U.S. Consumer Durables Stock News

Johnson Outdoors (JOUT) just closed FY 2025 with fourth quarter revenue of about $135.8 million and basic EPS of roughly -$2.83, alongside a trailing twelve month revenue base of about $592.4 million and basic EPS of around -$3.34. The company has seen quarterly revenue move from about $105.9 million in Q4 2024 to $135.8 million in Q4 2025, while quarterly EPS shifted from roughly -$3.35 to -$2.83 over the same period. This performance sets the stage for a potential earnings turnaround even...

If you are wondering whether Teleflex at around $126 is a bargain or a value trap, you are not alone. This article is going to unpack exactly what the market might be missing. The stock has bounced 5.3% over the last week and 13.8% over the last month, even though it is still down 29.1% year to date and 28.8% over the past year. This pattern often signals that investors are rethinking the balance between risk and reward. Recent coverage has focused on Teleflex sharpening its portfolio around...

Jazz Pharmaceuticals recently announced that multiple new data sets on its epilepsy drug Epidiolex and oncology candidate Ziihera were accepted for presentation at major medical meetings, including late-breaking clinical and real-world evidence results shared at the American Epilepsy Society 2025 conference. This wave of fresh data, spanning seizure control, treatment patterns, real-world outcomes, and potential synergy with other therapies, strengthens the clinical profile of two of Jazz’s...

Energy Fuels (UUUU) has quietly transformed from a niche uranium player into a broader critical minerals story, and the stock’s wild swings over the past year have many investors rethinking its long term risk reward. See our latest analysis for Energy Fuels. After a huge run up earlier in the year, the recent pullback, including a 7.9 percent 1 day share price return decline, looks more like a pause than a reversal when you zoom out to its 156.5 percent year to date share price return and 144...

Valaris (VAL) just locked in a multi year, $300 million drilling contract with Shell offshore Brazil, a long duration deal that immediately fattens its backlog and clarifies demand visibility into 2027. See our latest analysis for Valaris. The Shell win lands just as sentiment has cooled, with the 1 day share price return down 6.83 percent and the 7 day share price return off 9.68 percent. Even so, the year to date share price return still sits above 20 percent and the 1 year total...

Pagaya Technologies recently closed PAID 2025-8, a AAA-rated US$500 million asset-backed securitization backed by consumer loans originated on its network, bringing its year-to-date ABS funding for personal loans to about US$5.40 billion. The deal, which attracted broad investor participation, highlights ongoing confidence in Pagaya’s AI-driven credit platform and its ability to consistently secure large-scale funding in the securitization market. Next, we’ll explore how this latest US$500...

Wondering if Apple is still worth buying at these levels, or if most of the upside is already priced in? You are not alone. This article will walk through what the current share price really implies. Apple has delivered a 14.1% gain year to date and is up 12.7% over the last year. The last week was basically flat at around a 0.2% dip, and the past month saw a modest 1.8% rise, keeping it firmly in long-term compounder territory with a 110.0% 3 year and 125.7% 5 year return profile. Recent...

If you are wondering whether eToro Group is a beaten down opportunity or a value trap at current levels, you are not alone. This article will walk through what the numbers are really saying about the stock. Despite solid brand recognition, the share price has had a rough ride recently, falling about 11.8% over the last week, 8.2% over the past month, and 43.4% year to date. This naturally raises questions about whether the risk reward balance has shifted. Recent headlines have focused on...

In June 2025, Revolution Medicines announced that the US FDA granted Breakthrough Therapy Designation to its oral RAS(ON) inhibitor daraxonrasib for previously treated metastatic pancreatic ductal adenocarcinoma patients with KRAS G12 mutations, based on emerging clinical data. This designation not only aims to speed development and review, but also highlights Revolution Medicines’ specialized position in tackling RAS-driven cancers, an area with significant unmet need. Next, we’ll explore...

Why Amicus Therapeutics Stock Is Back on Investors Radar Amicus Therapeutics (FOLD) has quietly put together a strong rebound, with the stock up roughly 12% this month and more than 32% over the past 3 months, drawing fresh attention. See our latest analysis for Amicus Therapeutics. That recent 6.57% one day share price move, on top of a 30 day share price return of 12%, has pushed Amicus back toward the upper end of its yearly range. This suggests momentum is rebuilding even though the five...

In early December 2025, GitLab reported third-quarter results showing revenue rising to US$244.35 million year on year, alongside a shift from a US$29.1 million net profit to a US$8.28 million net loss and updated guidance calling for full-year 2026 revenue of about US$946 million–US$947 million. On the same day, GitLab also named veteran finance leader Jessica Ross as its incoming CFO, a move that could influence how the company balances rapid top-line growth with its widening losses and...

If you are wondering whether Kinder Morgan is still attractively priced today or if most of the upside is already reflected in the share price, this article will walk through what the numbers indicate about its current valuation. The stock has pulled back recently, with shares down around 3.7% over the last week and 1.0% over the past month, but longer-term holders are still sitting on gains of 78.2% over 3 years and 151.6% over 5 years. Recent moves have been influenced by ongoing debates...

Market context for First Horizon First Horizon (FHN) has quietly outperformed many regional peers this year, with the stock up about 20% over the past year and nearly 8% in the past month. This performance invites a closer look. See our latest analysis for First Horizon. With the share price now at $23.59 and a 1 month share price return of just over 8 percent, that recent momentum builds on a solid 1 year total shareholder return above 20 percent. This hints that investors are gradually...

Insulet (PODD) just picked up FDA 510(k) clearance for a major Omnipod 5 algorithm upgrade, adding a lower 100 mg/dL glucose target and smoother automation that could quietly reshape expectations for its growth story. See our latest analysis for Insulet. Even after the FDA news and upbeat commentary around faster EPS growth, Insulet’s share price return has cooled in recent weeks, with the stock now at $295.70. However, its positive year to date share price return and solid five year total...

Unum Group recently announced that its Board of Directors authorized a new share repurchase program of up to US$1,000 million, alongside completing a US$300 million senior notes offering due in 2035 to support capital flexibility. The combination of a sizable new buyback authorization and added debt financing underscores management’s willingness to deploy capital toward shareholder returns while maintaining balance-sheet optionality. We’ll now examine how Unum’s newly authorized US$1,000...

Wondering if NIKE at around $67 is a bargain in disguise or a value trap in plain sight? This article will cut through the noise and focus squarely on what the numbers say about its true worth. Despite a rough longer term run, with the stock down 32.8% over 3 years and 47.2% over 5 years, NIKE has shown a bit of life recently, gaining 2.4% over the last week and 5.1% over the last month, even though it remains down 8.4% year to date and 10.6% over the past year. Recent headlines have...

Earlier this month, PepsiCo outlined a multi-year turnaround plan shaped with activist investor Elliott Management, including cutting nearly 20% of its U.S. SKUs, closing manufacturing plants, reviewing its North American supply chain, and guiding to roughly flat 2025 earnings before targeting margin expansion and higher core EPS growth in 2026. At the same time, PepsiCo is shifting toward affordability and innovation, lowering some prices, launching products with simpler ingredients, and...

Earlier this month, Barclays upgraded Cboe Global Markets to Overweight, citing the company’s healthy growth in index options, rising retail options activity, and its sharpened focus on core derivatives while selling sub-scale businesses in regions such as Australia and Canada. Barclays also highlighted Cboe’s plan to extend Russell 2000 Index options to nearly 24-hour trading from February 2026, underscoring how expanded access to proprietary index products is becoming central to the...

Qfin Holdings (QFIN) is back on investors radar after fresh research highlighted it as a rare bright spot in China fintech, with its capital light, fee driven model standing out against broad sector pessimism. See our latest analysis for Qfin Holdings. Despite that upbeat narrative, the 30 day share price return of negative 14.8% and year to date share price return of negative 48.8% show sentiment is still fragile. This is true even though the 3 year total shareholder return of 28% and 5 year...

If you are wondering whether Citigroup is still a value play after such a big run, or if you have already missed the boat, you are in the right place to break that down calmly and clearly. The stock has climbed 2.7% over the last week, 8.7% over the last month, and an impressive 59.9% year to date, with a 61.8% gain over the past year and a massive 181.1% rise over three years. This performance has clearly shifted how the market views its risk and reward profile. Recent headlines have...

If you are wondering whether Vertiv Holdings Co is still a buy after its big run, you are not alone. This breakdown is going to focus squarely on what the current share price really implies about future returns. The stock has cooled off recently, down 14.7% over the last week and 7.0% over the past month, but it is still up 36.3% year to date and an eye catching 1131.2% over three years. This naturally raises the question of how much upside might be left versus the risk of a pullback. Behind...

Wondering if Apellis Pharmaceuticals is finally offering real value at today’s price, or if it is just another biotech value trap in disguise, you are not alone. The stock has jumped 6.8% over the last week and 26.0% over the past month, even though it is still down 23.9% year to date and 24.0% over the past year. This tells you sentiment has started to shift, but long-term holders may still be underwater. That recent surge has been driven largely by improving confidence in the commercial...

General Dynamics (GD) has quietly cooled off after a strong run this year, slipping about 3% over the past month even as its year to date gain still sits near 29%. See our latest analysis for General Dynamics. At around $337.49 per share, General Dynamics has eased back from recent highs. That softer 30 day share price return comes after a powerful year to date climb, with longer term total shareholder returns still suggesting momentum is cooling rather than collapsing. If you are reassessing...

If you are wondering whether Micron Technology is still a smart buy after its massive run up, or if the easy money has already been made, you are in the right place. The stock has surged 176.1% year to date and 136.2% over the last year. This comes even with a small 1.5% pullback in the past month and a 1.7% gain over the last week, which hints that investor expectations and perceived risk are shifting fast. Recent headlines have zeroed in on Micron as a key beneficiary of demand for high...